Login
$GH
$147.54 +$3.51 (2.44%) After hours

$GH 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening

03 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

PALO ALTO, Calif., — November 3, 2026 — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and curre...

03 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Global Performance-Based Restricted St...

30 Jul 2026 8-K: Results of Operations and Financial Condition

Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders (the “Annual Meeting”) of Guardant Health, Inc. (the “Company”) was held on June 17, 2026.

07 May 2026 8-K: Results of Operations and Financial Condition

First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening

27 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

19 Feb 2026 8-K: Results of Operations and Financial Condition

Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume

07 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE, dated as of November 7, 2025, between Guardant Health, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).

29 Oct 2025 8-K: Results of Operations and Financial Condition

Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data

24 Sep 2025 8-K: Regulation FD Disclosure

Guardant Health, Inc. (the “Company”) will host an Investor Day on September 24, 2025 beginning at 9:00 a.m. Eastern time in New York City. The presentation will include remarks from Helmy Eltoukhy and AmirAli Talasaz, co-Chief Executive...

15 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

PALO ALTO, Calif., September 15, 2025 -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary...

30 Jul 2025 8-K: Results of Operations and Financial Condition

Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders (the “Annual Meeting”) of Guardant Health, Inc. (the “Company”) was held on June 18, 2025.

30 Apr 2025 8-K: Results of Operations and Financial Condition

Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data

09 Apr 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On April 3, 2025, Guardant Health, Inc. (the “Company”) entered into a third amendment to the lease (“Third Amendment”) dated November 1, 2014 between the Company and Metropolitan Life Insurance Company (the “Landlord”), as amended on Oc...

20 Feb 2025 8-K: Results of Operations and Financial Condition

Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades

14 Feb 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

INDENTURE, dated as of February 14, 2025, between Guardant Health, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).

07 Feb 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Guardant Health, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “New Notes”). The New Notes will be convertible into cash, shares (“Underlying Shares”) of common stoc...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support